Skip to main content
SpringerLink
Log in

Urologic Cancer

  • Chapter
  • First Online:
Clinical PET and PET/CT

  • 2698 Accesses

Abstract

Positron emission tomography (PET) is a unique imaging modality with the capability of studying regional metabolism. 18F-fluoro-deoxyglucose (FDG) is the most widely used tracer in the field of PET oncology. The clinical utility of oncology PET using FDG has been proven in the staging and restaging of malignant tumors such as those in the head/neck, lung, breast, and colorectal cancers, as well as malignant lymphoma and melanoma. In the field of urology, FDG PET has been evaluated for relevant malignancies with promising results in certain areas and disappointing results in others. At present, FDG PET is capable of visualizing urologic tumors and associated lymph nodes and distal metastatic sites. However, its use is severely limited by excretion of the most commonly used radioisotope via the urinary tract, making pelvic imaging particularly unrewarding. 11C-choline, up-regulated in malignant cells, has shown potential usefulness in brain, prostate, and esophageal cancers with enhanced synthesis of membrane phospholipids. This chapter discusses the clinical usefulness of oncology PET in the field of urology, including renal cell, urinary bladder, and prostate cancer, as well as testicular tumors. We review the related articles of PET oncology in the field of urology.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Khandani AH, Rathmell WK. Positron emission tomography in renal cell carcinoma: an imaging ­biomarker in development. Semin Nucl Med. 2012;42(4):221–30.

    Article  PubMed  CAS  Google Scholar 

  2. Safei A, Figlin R, Hoh CK, et al. The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for restaging of renal cell cancer. Clin Nephrol. 2002;57:56–62.

    Google Scholar 

  3. Poggi MM, Patronas N, Buttman JA, et al. Intramedullary spinal cord metastasis from renal cell carcinoma: detection by positron emission tomography. Clin Nucl Med. 2001;26:837–9.

    Article  PubMed  CAS  Google Scholar 

  4. See WA, Fuller JR. Staging of advanced bladder cancer. Current concepts and pitfalls. Urol Clin North Am. 1992;19:663–83.

    PubMed  CAS  Google Scholar 

  5. Ahlstrom H, Malmstrom PU, Letocha H, et al. Positron emission tomography in the diagnosis and staging of urinary bladder cancer. Acta Radiol. 1996;37:180–5.

    PubMed  CAS  Google Scholar 

  6. Heicappell R, Muller-Mattheis V, Reinhardt M, et al. Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[(18)F]-2-deoxy-D-glucose. Eur Urol. 1999;36:582–7.

    Article  PubMed  CAS  Google Scholar 

  7. Hara T, Kosaka M, Kishi H. PET imaging of brain tumor with [methyl-11C] choline. J Nucl Med. 1997;38:842–7.

    PubMed  CAS  Google Scholar 

  8. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med. 1998;39:990–5.

    PubMed  CAS  Google Scholar 

  9. Inoue T, Oriuchi N, Tomiyoshi K, et al. A shifting landscape: what will be next FDG in PET oncology? Ann Nucl Med. 2002;16:1–9.

    Article  PubMed  Google Scholar 

  10. DeGrado TR, Baldwin SW, Wang S, et al. Synthesis and evaluation of F-18 labeled choline analogs as oncologic PET tracers. J Nucl Med. 2001;42:1805–14.

    PubMed  CAS  Google Scholar 

  11. Park H, Wood D, Hussain H, et al. Introducing parametric fusion PET/MRI of primary prostate cancer. J Nucl Med. 2012;53(4):546-51.

    PubMed  CAS  Google Scholar 

  12. Schuster DM, Votaw JR, Nieh PT, et al. Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med. 2007;48(1):56-63.

    PubMed  CAS  Google Scholar 

  13. Kitajima K, Nakamoto Y, Senda M, et al. Ann Nucl Med. 2007;21(7):405–10.

    Article  PubMed  CAS  Google Scholar 

  14. Spermon JR, De Geus-Oei LF, Kiemeney LA, et al. The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and restaging after chemotherapy for testicular germ cell tumours. BJU Int. 2002;89:549–56.

    Article  PubMed  CAS  Google Scholar 

  15. De Santis M, Bokemeyer C, Becherer A, et al. Predictive impact of 2-18-fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol. 2001;19:3740–4.

    PubMed  Google Scholar 

  16. Tsatalpas P, Beuthien-Baumann B, Kropp J, et al. Diagnostic value of F-18 FDG positron emission tomography for detection and treatment control of malignant germ cell tumors. Urol Int. 2002;68:157–63.

    Article  PubMed  Google Scholar 

  17. Cremerious U, Effert PJ, Adam G, et al. FDG PET for detection and therapy control of metastatic germ cell tumor. J Nucl Med. 1998;39:815–22.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiology, Yokohama City University Graduate School of Medicine, 3-9 Pukuura, Kanazawa-ku, Yokohama, 236-0004, Japan

    Tomio Inoue M.D., Ph.D. & Nobukazu Takahashi M.D., Ph.D.

  2. Department of Nuclear Medicine and Diagnostic Radiology, Gumma University School of Medicine, Maebashi, 371-8511, Japan

    Tetsuya Higuchi M.D., Ph.D.

  3. Departments of Nuclear Medicine and Diagnostic Radiology, The University of Texas MD Anderson Cancer Center and Medical School, 1515 Holcombe Blvd, 0059, Houston, TX, 77030, USA

    E. Edmund Kim M.D., M.S.

  4. Graduate School of Convergence Science and Technology, Seoul National University, Seoul, South Korea

    E. Edmund Kim M.D., M.S.

Authors
  1. Tomio Inoue M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nobukazu Takahashi M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tetsuya Higuchi M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. Edmund Kim M.D., M.S.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tomio Inoue M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. and Diagnostic Radiology, The University of Texas, Departments of Nuclear Medicine, Holcombe Blvd. 1515, Houston, 77030, Texas, USA

    E. Edmund Kim

  2. Gachon University School of Medicine, Department of Nuclear Medicine, Guwol-dong 1198, Namdong-Gu, Incheon, 405, Korea, Republic of (South Korea)

    Myung-Chul Lee

  3. Yokohama City University, Graduate School of Medicine, Department of Radiology, Fukuura 3-9, Yokohama, Kanagawa, 236-0004, Japan

    Tomio Inoue

  4. The University of Texas, MD Anderson Cancer Center, Dept. of Experimental Diagnostic Imaging, Holcombe Blvd. 1400, Houston, 77030, Texas, USA

    Wai-Hoi Wong

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Inoue, T., Takahashi, N., Higuchi, T., Kim, E.E. (2013). Urologic Cancer. In: Kim, E., Lee, MC., Inoue, T., Wong, WH. (eds) Clinical PET and PET/CT. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0802-5_25

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-0802-5_25

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4419-0801-8

  • Online ISBN: 978-1-4419-0802-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation